Caution! The site can't guarantee, that text has age permission. The site is not recommended, if you are less than 18 years old.
The site shows example sentences for English words. How the word or phrase could be used in a sentence?
" ... The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Letairis (ambrisentan) is an oral formulation of an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with World Health Organization (WHO) Class II or III symptoms to improve exercise capacity and delay clinical worsening. It sublicensed to GSK the rights to ambrisentan, marketed by GSK as Volibris (ambrisentan), for PAH in territories outside of the United States. Ranexa (ranolazine) is an extended-release tablet for the treatment of chronic angina. The Company has licensed to Menarini International Operations Luxembourg SA the rights to Ranexa in territories outside of the United States. Lexiscan/Rapiscan (regadenoson) injection is indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress. Astellas US LLC (Astellas) has rights to manufacture and sell regadenoson under the name Lexiscan in the United States. Rapidscan Pharma Solutions, Inc. (RPS) holds the right to manufacture and sell regadenoson under the name Rapiscan in Europe and certain territories outside the United States. The Company receives royalties from Astellas and RPS for sales in these territories. Eleclazine, formerly GS-6615, a late sodium channel inhibitor, is being evaluated in Phase III clinical trials for the treatment of Long QT-3 Syndrome. Eleclazine is also being evaluated in Phase II clinical trials for the treatment of hypertrophic cardiomyopathy and ventricular tachycardia/ventricular fibrillation. It is also evaluating GS-4977, an ASK-1 inhibitor, for pulmonary arterial hypertension in Phase II clinical trials. ... "